{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T23:12:49Z","timestamp":1774048369246,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cell Biology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ejcb.2022.151238","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T22:35:46Z","timestamp":1652999746000},"page":"151238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The PRC2 molecule EED is a target of epigenetic therapy for neuroblastoma"],"prefix":"10.1016","volume":"101","author":[{"given":"Dilibaerguli","family":"Shaliman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisanori","family":"Takenobu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi P.","family":"Sugino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Kamijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejcb.2022.151238_bib1","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3390\/biom11081112","article-title":"How do telomere abnormalities regulate the biology of neuroblastoma?","volume":"11","author":"Akter","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejcb.2022.151238_bib2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1101\/gr.075671.107","article-title":"Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy","volume":"19","author":"Attiyeh","year":"2009","journal-title":"Genome Res"},{"key":"10.1016\/j.ejcb.2022.151238_bib3","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.bjc.6603777","article-title":"Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium","volume":"96","author":"Blaheta","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejcb.2022.151238_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246244","article-title":"EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth","volume":"16","author":"Bownes","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ejcb.2022.151238_bib5","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/ncomms4127","article-title":"The central role of EED in the orchestration of polycomb group complexes","volume":"5","author":"Cao","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejcb.2022.151238_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molcel.2004.06.020","article-title":"SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex","volume":"15","author":"Cao","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejcb.2022.151238_bib7","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1076997","article-title":"Role of histone H3 lysine 27 methylation in polycomb-group silencing","volume":"298","author":"Cao","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejcb.2022.151238_bib8","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1128\/MCB.21.13.4330-4336.2001","article-title":"The polycomb-group gene Ezh2 is required for early mouse development","volume":"21","author":"Carroll","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejcb.2022.151238_bib9","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1101\/gad.217778.113","article-title":"The histone H3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression","volume":"27","author":"Chan","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejcb.2022.151238_bib10","doi-asserted-by":"crossref","first-page":"13049","DOI":"10.18632\/oncotarget.3790","article-title":"Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejcb.2022.151238_bib11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1172\/JCI90793","article-title":"CRISPR-CAS9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2","volume":"128","author":"Chen","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejcb.2022.151238_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0092-8674(02)00975-3","article-title":"Drosophila enhancer of Zeste\/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites","volume":"111","author":"Czermin","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.ejcb.2022.151238_bib13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","article-title":"Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors","volume":"34","author":"Duenas-Gonzalez","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejcb.2022.151238_bib14","unstructured":"Endo, Y., Sugino, R. P., Takenobu, H., Mukae, K., Okada, R., Shinno, Y., Haruta, M., Satoh, S., Akter, J., Hattori, N., Kamijo, T., Epigenetic pathways control MYCN-related tumor suppressors and core transcription factors in neuroblastoma. In preparation."},{"key":"10.1016\/j.ejcb.2022.151238_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1242\/dev.121.2.273","article-title":"The eed mutation disrupts anterior mesoderm production in mice","volume":"121","author":"Faust","year":"1995","journal-title":"Development"},{"key":"10.1016\/j.ejcb.2022.151238_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.canlet.2014.03.022","article-title":"RASSF1A methylation may have two biological roles in neuroblastoma tumorigenesis depending on the ploidy status and age of patients","volume":"348","author":"Haruta","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejcb.2022.151238_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nchembio.2306","article-title":"The EED protein\u2013protein interaction inhibitor A-395inactivates the PRC2 complex","volume":"13","author":"He","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejcb.2022.151238_bib18","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1126\/science.aac4383","article-title":"Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex2","volume":"350","author":"Jiao","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejcb.2022.151238_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0077-2","article-title":"Targeting of epigenetic regulators in neuroblastoma","volume":"50","author":"Jubierre","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejcb.2022.151238_bib20","doi-asserted-by":"crossref","first-page":"11316","DOI":"10.1038\/ncomms11316","article-title":"Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2","volume":"7","author":"Justin","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejcb.2022.151238_bib21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/pr.2011.54","article-title":"Role of stemness-related molecules in neuroblastoma","volume":"71","author":"Kamijo","year":"2012","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ejcb.2022.151238_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1006\/cyto.2002.1966","article-title":"Synergism between stem cell factor and granulocyte-macrophage colony- stimulating factor on cell proliferation by induction of cyclins","volume":"19","author":"Kamijo","year":"2002","journal-title":"Cytokine"},{"key":"10.1016\/j.ejcb.2022.151238_bib23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nchembio.1331","article-title":"Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer","volume":"9","author":"Kim","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejcb.2022.151238_bib24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejcb.2022.151238_bib25","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/sj.onc.1210672","article-title":"Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells","volume":"27","author":"Kurata","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejcb.2022.151238_bib26","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1101\/gad.1035902","article-title":"Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein","volume":"16","author":"Kuzmichev","year":"2002","journal-title":"Genes Dev"},{"key":"10.1016\/j.ejcb.2022.151238_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1097-2765(04)00185-6","article-title":"Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3","volume":"14","author":"Kuzmichev","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejcb.2022.151238_bib28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cell.2006.02.043","article-title":"Control of developmental regulators by Polycomb in human embryonic stem cells","volume":"125","author":"Lee","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ejcb.2022.151238_bib29","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1038\/s41388-018-0133-3","article-title":"EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications","volume":"37","author":"Li","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.ejcb.2022.151238_bib30","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41588-019-0517-5","article-title":"The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy","volume":"51","author":"Lindeboom","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejcb.2022.151238_bib31","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.2174\/1389200221666191226102231","article-title":"Neuroblastoma: an updated review on biology and treatment","volume":"20","author":"Mallepalli","year":"2019","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejcb.2022.151238_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejcb.2022.151238_bib33","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature08398","article-title":"Role of the polycomb protein EED in the propagation of repressive histone marks","volume":"461","author":"Margueron","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejcb.2022.151238_bib34","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMra0804577","article-title":"Recent advances in neuroblastoma","volume":"362","author":"Maris","year":"2010","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejcb.2022.151238_bib35","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","article-title":"Neuroblastoma","volume":"369","author":"Maris","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejcb.2022.151238_bib36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejcb.2022.151238_bib37","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/mol.65.3.520","article-title":"Valproic acid inhibits angiogenesis in vitro and in vivo","volume":"65","author":"Michaelis","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejcb.2022.151238_bib38","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jmb.2007.10.040","article-title":"Molecular and functional mapping of EED motifs required for PRC2-dependent histone methylation","volume":"374","author":"Montgomery","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejcb.2022.151238_bib39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0092-8674(02)00976-5","article-title":"Histone methyltransferase activity of a Drosophila Polycomb group repressor complex","volume":"111","author":"M\u00fcller","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.ejcb.2022.151238_bib40","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1038\/onc.2010.22","article-title":"Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1B \u03b2 and TSLC1 in neuroblastoma","volume":"29","author":"Ochiai","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ejcb.2022.151238_bib41","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ccr.2005.03.019","article-title":"Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas","volume":"7","author":"Ohira","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejcb.2022.151238_bib42","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/nature14980","article-title":"Telomerase activation by genomic rearrangements in high-risk neuroblastoma","volume":"526","author":"Peifer","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejcb.2022.151238_bib43","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2014.59.4648","article-title":"Advances in risk classification and treatment strategies for neuroblastoma","volume":"33","author":"Pinto","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcb.2022.151238_bib44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ng.2529","article-title":"The genetic landscape of high-risk neuroblastoma","volume":"45","author":"Pugh","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejcb.2022.151238_bib45","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ccell.2019.09.002","article-title":"ATRX in-frame fusion neuroblastoma is sensitive to EZH2 inhibition via modulation of neuronal gene signatures","volume":"36","author":"Qadeer","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejcb.2022.151238_bib46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nchembio.2304","article-title":"An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED","volume":"13","author":"Qi","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejcb.2022.151238_bib47","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00441-018-2820-3","article-title":"Genetic susceptibility to neuroblastoma: current knowledge and future directions","volume":"372","author":"Ritenour","year":"2018","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.ejcb.2022.151238_bib48","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nrd.2017.179","article-title":"WD-repeat domain proteins: a novel target class?","volume":"16","author":"Schapira","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejcb.2022.151238_bib49","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/aps.2017.7","article-title":"Structure of the PRC2 complex and application to drug discovery","volume":"38","author":"Shi","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejcb.2022.151238_bib50","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrm2763","article-title":"Mechanisms of polycomb gene silencing: knowns and unknowns","volume":"10","author":"Simon","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejcb.2022.151238_bib51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/onc.2010.383","article-title":"CD133 suppresses neuroblastoma cell differentiation via signal pathway modification","volume":"30","author":"Takenobu","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.ejcb.2022.151238_bib52","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/75007","article-title":"Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN","volume":"6","author":"Teitz","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejcb.2022.151238_bib53","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/cncr.29848","article-title":"Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: a report from the International Neuroblastoma Risk Group project","volume":"122","author":"Thompson","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejcb.2022.151238_bib54","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1158\/0008-5472.CAN-16-3144","article-title":"PRC2-mediated transcriptomic alterations at the embryonic stage govern tumorigenesis and clinical outcome in MYCN-driven neuroblastoma","volume":"77","author":"Tsubota","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejcb.2022.151238_bib55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1158\/0008-5472.CAN-11-0961","article-title":"EZH2 mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR","volume":"72","author":"Wang","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejcb.2022.151238_bib56","doi-asserted-by":"crossref","first-page":"14413","DOI":"10.18632\/oncotarget.24214","article-title":"The protective autophagy activated by GANT-61 in MYCN amplified neuroblastoma cells is mediated by PERK","volume":"18","author":"Wang","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejcb.2022.151238_bib57","doi-asserted-by":"crossref","first-page":"19266","DOI":"10.1073\/pnas.1008937107","article-title":"Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2)","volume":"107","author":"Xu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejcb.2022.151238_bib58","first-page":"1","article-title":"Preclinical pharmacolokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment","volume":"48","author":"Zhang","year":"2021","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejcb.2022.151238_bib59","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1158\/1078-0432.CCR-17-1716","article-title":"A combination of SAHA and quinacrine is effective in inducing cancer cell death in upper gastrointestinal cancers","volume":"24","author":"Zhu","year":"2018","journal-title":"Clin. Cancer Res."}],"container-title":["European Journal of Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171933522000413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171933522000413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T17:24:48Z","timestamp":1759253088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0171933522000413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0171933522000413"],"URL":"https:\/\/doi.org\/10.1016\/j.ejcb.2022.151238","relation":{},"ISSN":["0171-9335"],"issn-type":[{"value":"0171-9335","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The PRC2 molecule EED is a target of epigenetic therapy for neuroblastoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cell Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejcb.2022.151238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"151238"}}